Based on next-generation sequencing analysis, genetic alteration in Akt1 (E17K and other pathologic mutations) was significantly enriched in metastatic breast cancer compared to primary breast cancer and Akt1, but not Akt2 or Akt3, was identified as an actionable target [61]. This evidence concerns the gene AKT1 and breast carcinoma.